HIMS
Hims & Hers Health, Inc.36.86
+0.61+1.68%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Reaffirms growth; adds buyback details.
Q&A largely reaffirmed prepared remarks' growth story, with management confidently detailing levers for core reacceleration like diagnostics, menopause, and testosterone amid headwinds from sexual health shifts and GLP-1 shipping cadences normalizing H2 2026. Andrew outlined a marketing pivot to brand-building for non-stigmatized longevity testing, enabling global platform ambitions. Yemi confirmed weight loss on track for $725M+ and opportunistic buybacks when undervalued, behind growth investments. Hers nears $1B in 2026 via diverse drivers. Buybacks activate on valuation gaps. Investors watch international scaling and investment payback.
Key Stats
Market Cap
8.39BP/E (TTM)
69.55Basic EPS (TTM)
0.53Dividend Yield
0%Recent Filings
8-K
New $250M buyback authorized
Hims & Hers Health authorized a $250 million share repurchase program on November 13, 2025, set to expire November 11, 2028, allowing flexible buybacks amid market conditions. This follows the full exhaustion of its prior $100 million program, with 1,334,572 shares repurchased for $55.5 million from October 1 through November 7, 2025. Repurchases signal confidence in valuation. The program remains discretionary and suspendable.
8-K
Q3 revenue jumps 49%
Hims & Hers Health reported Q3 2025 revenue of $599 million, surging 49% year-over-year, fueled by 21% subscriber growth to 2.5 million and 19% higher monthly online revenue per subscriber at $80. Adjusted EBITDA climbed 53% to $78 million, while gross margin dipped to 74% from 79% due to weight-loss fulfillment costs. The company narrowed full-year guidance to $2.335-$2.355 billion in revenue and $307-$317 million in Adjusted EBITDA. Active talks with Novo Nordisk for Wegovy access could broaden offerings, yet no deal is finalized.
10-Q
Q3 FY2025 results
Hims & Hers Health surged ahead in Q3 FY2025 ended September 30, 2025, with revenue hitting $599.0M, up 49% y/y and 26% q/q (derived), fueled by personalized offerings that now claim 70% of online sales. Gross margin dipped to 74% from 79% y/y amid higher fulfillment costs for new products, yet operating income stayed positive at $11.8M, down from $22.4M y/y, while diluted EPS fell to $0.06 from $0.32 y/y—reconciled against 248.7M shares with no anti-dilution flagged. Free cash flow remained robust at $79.4M for the quarter (derived from $148.7M operating cash minus $69.4M capex), bolstering $346M cash and $722M investments, offset by $971M in 0% convertible notes due 2030. The Zava acquisition closed in July 2025 for $258M (cash/contingent), adding $142M goodwill and $100M platform partnerships amortized over 12 years, while $168M revolver availability supports liquidity sans covenants breached. Competition from traditional providers sharpens pricing pressures.
8-K
COO transition announced
Hims & Hers Health announced on September 28, 2025, that COO Nader Kabbani will transition to an advisory role effective November 2, 2025, providing strategic guidance through July 2026. Mike Chi, current Chief Commercial Officer with over 20 years in consumer internet, steps up to COO, consolidating operations, marketing, product, and commercial functions. This shift streamlines leadership amid growth. No compensation changes yet.
8-K
Company communication channels listed
Hims & Hers Health, Inc. filed an 8-K on September 22, 2025, under Item 8.01 to outline its communication channels for public disclosures. The company lists key platforms including websites like hims.com and forhers.com, investor relations at investors.hims.com, news site, X accounts (@wearehims, @wearehers, @himsherscomms, @AndrewDudum), and LinkedIn pages. This setup ensures broad, non-exclusionary distribution of material information to investors. No specific business event or financial impact is disclosed.
IPO
Website
Employees
Sector
Industry
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
DOCS
Doximity, Inc.
43.80-0.85
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
IMCC
IM Cannabis Corp.
1.73+0.21
LFMD
LifeMD, Inc.
3.42+0.15
MGRX
Mangoceuticals, Inc.
1.20+0.06
MRMD
MariMed Inc.
0.12+0.01
OVATF
OVATION SCIENCE INC
0.03+0.00
TDOC
Teladoc Health, Inc.
7.41+0.07
ZTS
Zoetis Inc.
123.23+2.25